Prof. Fu Wang
School of Basic Medicine, Xi'an Jiaotong University, China
Biography: Professor and doctoral advisor of the School of Basic Medicine of the Medical Department of Xi'an Jiaotong University, Class A young top talents, chair professor of the "Minjiang Scholars Award Program" in Fujian Province, and associate editor of Frontiers in Oncology (IF 6.1) and Frontiers in Medicine (IF 5.0) magazines. Mainly engaged in research in biomedical imaging and tumor diagnosis and treatment. He has successively presided over several fund projects including the National Natural Science Foundation of China (2 general projects and 1 youth project), the second-level sub-project of the National "973 Plan", the general project of the Shaanxi Provincial Natural Science Foundation, and the preferential support project for scientific and technological activities of overseas Chinese in Shaanxi Province (2 excellent projects); As the backbone of the project, he participated in such scientific research projects as the National "973" Plan, the National Natural Science Foundation's major projects, and the Ministry of Science and Technology's support plan. In recent years, he has published more than 40 SCI papers in PNAS, Nature Protocols, Nuclear Acids Research, Molecular Therapy, Oncogene, Cancer Letters and other international mainstream journals as the first author/corresponding author; Apply for/authorize more than 10 Chinese invention patents; The research achievements won the first prize of the Science and Technology Award of Shaanxi Provincial Institutions of Higher Learning and the third prize of the Science and Technology Award of Shaanxi Province.
Speech Title：Genetically encoded probes for accurate imaging in vivo
Prof. Ziyuan Wang
Xuzhou Innovative Biomedical High-tech Key Experiment, China
Biography:
A. The combination and delivery of blood substitutes for O2 is also an urgent drug for clinical surgery and trauma emergency treatment. The preparation of recombinant human hemoglobin based oxygen carriers (HBOCs) has been my research interest for many years.
B. Ischemic cardio-cerebrovascular disease is the largest unmet patient demand of human life. The number of deaths in the world is 15 million each year, and about 3 million in China. The traditional thrombolytic therapy and percutaneous coronary intervention therapy are blank before the opening of blood vessels. There is an urgent need for an emergency medicine that can effectively restore the oxygen supply in the early stage of the disease to reduce the mortality and disability rate. In view of the clinical gap of first aid for myocardial infarction and cerebral infarction, I developed a new first-aid drug with innovative mechanism of "ischemia without hypoxia", which can seamlessly link thrombolysis and percutaneous coronary intervention, and benefit the majority of patients.
C. Liver specific gene therapy carrier platform: liver specific gene therapy carrier is the premise of liver gene therapy. Harmless hepatitis B virus is the best vector for gene therapy of liver genetic diseases and infectious diseases; At the same time, it can also use the liver to express other drug proteins, such as insulin, to develop better treatment techniques and drugs for diabetes.
D. Gene therapy to eliminate cccDNA and cure hepatitis B: hepatitis B has now been functionally cured, but the cccDNA in the patient's liver cell nucleus is the source of recurrence and deterioration of hepatitis B. Complete elimination is the complete cure.
The project uses gene therapy technology to package the nucleic acid-degrading biological drug for treatment in a specific cell line in virus particles, infect liver cells and deliver the biological drug to the nucleus in a targeted manner, resulting in a cure effect of degrading cccDNA. This will be a bonus for patients brought by the development of the times, which has great social significance and economic value.
Speech Title：Research and development of emergency medicine and oxygen carrier for acute myocardial infarction and cerebral infarction
Prof.Junfeng Shi
School of Biomedical Sciences, Hunan University
Biography：Junfeng Shi, a professor and doctoral supervisor at the School of Biomedical Sciences, Hunan University. He has been selected as “national high-level young talent” and “Hunan Province distinguished Youth”. He received his PhD in Chemistry from Brandeis University (2009-2015) and subsequently worked as a postdoctoral researcher at the National Cancer Institute (NCI, NIH) in the United States. In September 2019, he joined Hunan University as a full professor. He has long been engaged in research on peptide pharmaceutical engineering and has published 66 papers in international high-level journals such as Nat. Nanotechnol., J. Am. Chem. Soc., and Angew. Chem. In. Ed., with more than 5400 citations and an H-index of 36. His achievements have been reported multiple times by the American national media, C@EN, and he has co-authored one English book. He has applied 11 patents, including two PCT patents and one US patent. Currently, he is leading over ten projects including National Natural Science Foundation of China, Hunan Province Innovation Talent Program, and several biopharmaceutical company projects.
Speech Title：From Supramolecular Hydrogel to Peptide Drug